Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of apatinib combined with irinotecan as second-line treatment for advanced gastric cancer
ChiCTR1900021377Phase 2Recruiting
- Sponsor
- The First Affiliated Hospital of Sun Yat-sen University
- Start
- Jan 2019
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Rivoceranib and irinotecan in gastric cancer (GC) and gastroesophageal junction adenocarcinoma, sponsored by The First Affiliated Hospital of Sun Yat-sen University. Primary endpoint: Progression-free survival. Started Jan 2019; status: recruiting.
02
Drugs
Rivoceranibirinotecan
03
Conditions
gastric cancer (GC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on ChiCTR1900021377.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900021377.